Skip to main content

Table 4 Comparing baseline and end of treatment data in Gp2 (N = 81)

From: Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study

Parameter

Baseline

Week 12

P-value

ALT (IU/L)

31.0 (3.0–121.0)

18.0 (4.0–59.0)

< 0.001

AST (IU/L)

31.0 (9.4–122.0)

24.0 (6.0–64.0)

< 0.001

Albumin (g/dL)

4.2 (2.9–5.9)

4.1 (2.6–5.3)

0.628

Total bilirubin (mg/dL)

0.7 (0.1–2.9)

0.9 (0.2–3.7)

< 0.001

WBCs (109/L)

6.3 (2.5–13.6)

6.2 (3.0–13.0)

0.324

HB (%)

13.8 (8.0–17.0)

12.0 (7.0–16.5)

< 0.001

Creatinine (mg/dl)

0.9 (0.4–2.0)

0.9 (0.5–1.4)

0.280

Platelet count (109/L)

203.0 (100.0–414.0)

212.0 (100–441.0)

0.856

  1. Values are presented as median (range)
  2. ALT alanine aminotransferase, AST aspartate aminotransferase, WBCs white blood cells, HB hemoglobin, P value ≤ 0.05 is considered significant
  3. Gp2 received sofosbuvir 400 mg/day plus ombitasvir 25 mg, paritaprevir 150 mg and ritonavir 100 mg/day plus ribavirin 15 mg/kg/day for 12 weeks